Physician profile
Latisha M Fleming
NPI 1205128725
$3,406.84
in general payments reported to CMS, 2019-2025
33 companies · $1,445 in 2025
The $1,445 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $719 · 2022: $589 · 2023: $292 · 2024: $362 · 2025: $1,445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,098.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,098.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $934.79 | 2021-2025 | |
| Janssen Biotech, INC. | $300.07 | 2023-2025 | Tremfya, Stelara, Symtuza |
| Ipsen Biopharmaceuticals, INC | $259.70 | 2025 | Iqirvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $196.12 | 2021-2025 | Xifaxan |
| Gilead Sciences, INC. | $195.12 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $174.80 | 2022-2024 | Dificid, Recarbrio, Zerbaxa |
| Takeda Pharmaceuticals U.S.A., INC. | $135.39 | 2021-2025 | Entyvio |
| Nestle Healthcare Nutrition INC. | $119.88 | 2021-2022 | |
| Celltrion USA INC. | $111.01 | 2024-2025 | Vegzelma |
| Astellas Pharma US INC | $97.16 | 2021 | |
| Intercept Pharmaceuticals, INC. | $88.70 | 2021-2025 | Ocaliva |
| Ardelyx, INC. | $82.79 | 2024-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $82.40 | 2024-2025 | Zenpep |
| Melinta Therapeutics, LLC | $73.17 | 2023-2024 | Kimyrsa, Vabomere, Rezzayo |
| Paratek Pharmaceuticals, INC. | $71.91 | 2022-2024 | Nuzyra |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $58.18 | 2022-2024 | Fetroja |
| Theratechnologies INC. | $52.24 | 2022-2023 | Egrifta, Trogarzo |
| Lilly USA, LLC | $41.14 | 2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $40.37 | 2025 | Voquezna |
| Orphalan INC | $37.88 | 2025 | Cuvrior |
| Alnylam Pharmaceuticals INC. | $34.79 | 2022-2023 | Givlaari |
| Braintree Laboratories, INC. | $31.55 | 2021-2025 | Suflave, Sutab |
| Viiv Healthcare Company | $23.12 | 2023 | Rukobia |
| Novartis Pharmaceuticals Corporation | $21.85 | 2024 | |
| Genzyme Corporation | $20.65 | 2025 | |
| Qiagen, LLC | $20.00 | 2022 | |
| Novo Nordisk INC | $19.77 | 2025 | Wegovy, Saxenda |
| Celgene Corporation | $16.91 | 2021 | |
| Renalytix Ai, INC. | $14.31 | 2022 | |
| Azurity Pharmaceuticals, INC. | $14.15 | 2025 | Sutab |
| La Jolla Pharmaceutical Company | $13.96 | 2023 | Xerava |
| Ironwood Pharmaceuticals, INC | $11.59 | 2021 | |
| Daiichi Sankyo INC. | $11.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Latisha Fleming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.